Fumihiko Takeshita
R&D Division
Tokyo, Japan
Tokyo, Japan
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 19 publications
Immunogenicity and safety of DS-5670d, an omicron XBB.1.5-targeting COVID-19 mRNA vaccine: A phase 3, randomized, active-controlled study.
Journal: PLoS medicine
Published: October 29, 2024
Protective effects of an mRNA vaccine candidate encoding H5HA clade 2.3.4.4b against the newly emerged dairy cattle H5N1 virus.
Journal: EBioMedicine
Published: August 29, 2024
Booster vaccination using bivalent DS-5670a/b is safe and immunogenic against SARS-CoV-2 variants in children aged 5-11 years: a phase 2/3, randomized, active-controlled study.
Journal: Frontiers in immunology
Published: June 07, 2024
Effectiveness, immunogenicity and safety of monovalent DS-5670a and bivalent DS-5670a/b SARS-CoV-2 vaccines: results from two randomized, active-comparator, non-inferiority trials.
Journal: Communications medicine
Published: May 16, 2024
DS-5670a, a novel mRNA-encapsulated lipid nanoparticle vaccine against severe acute respiratory syndrome coronavirus 2: Results from a phase 2 clinical study.
Journal: Vaccine
Published: November 08, 2022
Fever Responses Are Enhanced with Advancing Age during Respiratory Syncytial Virus Infection among Children under 24 Months Old.
Journal: The Tohoku journal of experimental medicine
Published: July 27, 2018
Age-Specific Profiles of Antibody Responses against Respiratory Syncytial Virus Infection.
Journal: EBioMedicine
Published: November 08, 2016
Ligand-induced Ordering of the C-terminal Tail Primes STING for Phosphorylation by TBK1.
Journal: EBioMedicine
Published: April 21, 2016
Efficient antigen delivery to the draining lymph nodes is a key component in the immunogenic pathway of the intradermal vaccine.
Journal: Journal of dermatological science
Published: October 13, 2015
Last Updated: 09/26/2026